| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 19 | 2026 | 212 | 4.460 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2026 | 29 | 2.300 |
Why?
|
| Immune System Diseases | 6 | 2026 | 55 | 2.240 |
Why?
|
| STAT3 Transcription Factor | 8 | 2026 | 228 | 2.120 |
Why?
|
| Gain of Function Mutation | 11 | 2022 | 116 | 2.020 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 5 | 2022 | 158 | 1.840 |
Why?
|
| Janus Kinases | 7 | 2026 | 36 | 1.830 |
Why?
|
| Severe Combined Immunodeficiency | 8 | 2024 | 108 | 1.790 |
Why?
|
| Killer Cells, Natural | 10 | 2025 | 351 | 1.550 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 15 | 2026 | 1275 | 1.450 |
Why?
|
| STAT1 Transcription Factor | 6 | 2021 | 84 | 1.170 |
Why?
|
| Pyrazoles | 5 | 2020 | 354 | 1.130 |
Why?
|
| Granulomatous Disease, Chronic | 4 | 2020 | 70 | 1.070 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2020 | 164 | 0.750 |
Why?
|
| Wiskott-Aldrich Syndrome | 4 | 2026 | 25 | 0.730 |
Why?
|
| STAT5 Transcription Factor | 3 | 2023 | 93 | 0.680 |
Why?
|
| STAT Transcription Factors | 3 | 2024 | 25 | 0.650 |
Why?
|
| Knee | 1 | 2019 | 21 | 0.600 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2019 | 24 | 0.600 |
Why?
|
| Mutation | 14 | 2023 | 6069 | 0.600 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2019 | 11 | 0.590 |
Why?
|
| Edema | 1 | 2019 | 129 | 0.560 |
Why?
|
| Pneumonia | 1 | 2022 | 340 | 0.560 |
Why?
|
| Humans | 71 | 2026 | 130138 | 0.550 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 371 | 0.530 |
Why?
|
| Lymphoma | 1 | 2020 | 327 | 0.530 |
Why?
|
| Fever | 1 | 2019 | 313 | 0.500 |
Why?
|
| Genetic Testing | 4 | 2022 | 1106 | 0.500 |
Why?
|
| Autoimmune Diseases | 5 | 2023 | 257 | 0.500 |
Why?
|
| Cytokines | 5 | 2022 | 1342 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 565 | 0.470 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 891 | 0.460 |
Why?
|
| Child, Preschool | 21 | 2026 | 15010 | 0.460 |
Why?
|
| Child | 25 | 2026 | 26183 | 0.440 |
Why?
|
| Infant | 17 | 2026 | 13279 | 0.440 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2021 | 883 | 0.440 |
Why?
|
| Transcription Factors | 1 | 2022 | 2402 | 0.380 |
Why?
|
| Adolescent | 21 | 2026 | 20803 | 0.380 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 30 | 0.360 |
Why?
|
| Genome, Human | 1 | 2018 | 1315 | 0.340 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1692 | 0.320 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1932 | 0.320 |
Why?
|
| Multifactorial Inheritance | 2 | 2025 | 172 | 0.320 |
Why?
|
| Lymphopenia | 2 | 2024 | 34 | 0.320 |
Why?
|
| Male | 27 | 2026 | 64395 | 0.310 |
Why?
|
| Signal Transduction | 5 | 2026 | 4653 | 0.300 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 215 | 0.300 |
Why?
|
| Agammaglobulinemia | 2 | 2022 | 43 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2025 | 3407 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 336 | 0.280 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2025 | 323 | 0.270 |
Why?
|
| Autoimmunity | 3 | 2022 | 175 | 0.270 |
Why?
|
| Rheumatic Diseases | 1 | 2019 | 77 | 0.270 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 688 | 0.270 |
Why?
|
| Female | 29 | 2026 | 70275 | 0.270 |
Why?
|
| Herpesvirus 4, Human | 2 | 2021 | 639 | 0.250 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2017 | 29 | 0.250 |
Why?
|
| Sepsis | 2 | 2021 | 496 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2024 | 501 | 0.240 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 258 | 0.240 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2026 | 354 | 0.240 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2017 | 65 | 0.240 |
Why?
|
| Coatomer Protein | 1 | 2016 | 28 | 0.240 |
Why?
|
| Sirolimus | 1 | 2018 | 231 | 0.240 |
Why?
|
| Th1 Cells | 1 | 2017 | 159 | 0.240 |
Why?
|
| Th17 Cells | 1 | 2017 | 97 | 0.240 |
Why?
|
| Young Adult | 12 | 2026 | 9988 | 0.240 |
Why?
|
| Tuberculosis | 1 | 2022 | 555 | 0.230 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 221 | 0.230 |
Why?
|
| Flow Cytometry | 2 | 2026 | 766 | 0.230 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2025 | 10 | 0.220 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 289 | 0.220 |
Why?
|
| Myosin Type V | 1 | 2025 | 9 | 0.220 |
Why?
|
| Infant, Newborn | 9 | 2025 | 8553 | 0.220 |
Why?
|
| Interleukin-9 | 1 | 2024 | 7 | 0.220 |
Why?
|
| Immunophenotyping | 3 | 2018 | 331 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2020 | 271 | 0.220 |
Why?
|
| Immunological Synapses | 2 | 2019 | 32 | 0.210 |
Why?
|
| Penetrance | 1 | 2025 | 108 | 0.210 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 2 | 2023 | 9 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 613 | 0.200 |
Why?
|
| Transplantation Conditioning | 3 | 2026 | 327 | 0.200 |
Why?
|
| Mutation, Missense | 2 | 2020 | 922 | 0.200 |
Why?
|
| Nitriles | 4 | 2020 | 161 | 0.200 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 208 | 0.200 |
Why?
|
| Adult | 16 | 2026 | 31039 | 0.200 |
Why?
|
| Phospholipase C gamma | 1 | 2023 | 27 | 0.200 |
Why?
|
| Eczema | 1 | 2023 | 35 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2023 | 25 | 0.200 |
Why?
|
| Leukopenia | 1 | 2023 | 44 | 0.190 |
Why?
|
| Primary Myelofibrosis | 1 | 2023 | 51 | 0.180 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 55 | 0.180 |
Why?
|
| UDPglucose 4-Epimerase | 1 | 2021 | 7 | 0.170 |
Why?
|
| Galactosemias | 1 | 2021 | 13 | 0.170 |
Why?
|
| Cohort Studies | 2 | 2022 | 5042 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2022 | 345 | 0.170 |
Why?
|
| Pyrimidines | 4 | 2020 | 454 | 0.170 |
Why?
|
| Cell Proliferation | 3 | 2024 | 2461 | 0.170 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2021 | 50 | 0.160 |
Why?
|
| Laboratories | 1 | 2021 | 80 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1588 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2025 | 558 | 0.160 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 19 | 0.160 |
Why?
|
| France | 1 | 2020 | 90 | 0.160 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1710 | 0.160 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 32 | 0.160 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2020 | 31 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 228 | 0.150 |
Why?
|
| Mycobacterium avium Complex | 1 | 2019 | 20 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 158 | 0.150 |
Why?
|
| Animals | 6 | 2026 | 33687 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 156 | 0.150 |
Why?
|
| Heterozygote | 3 | 2018 | 722 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2020 | 197 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 197 | 0.140 |
Why?
|
| Thymus Gland | 2 | 2023 | 105 | 0.140 |
Why?
|
| Homozygote | 1 | 2020 | 534 | 0.140 |
Why?
|
| Actins | 1 | 2020 | 314 | 0.140 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 2 | 2018 | 5 | 0.140 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2018 | 38 | 0.140 |
Why?
|
| Alemtuzumab | 1 | 2018 | 89 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 239 | 0.130 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 511 | 0.130 |
Why?
|
| Inflammation | 3 | 2021 | 1481 | 0.130 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 173 | 0.130 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2017 | 84 | 0.130 |
Why?
|
| Arthritis | 2 | 2019 | 82 | 0.130 |
Why?
|
| Cell Differentiation | 3 | 2024 | 1908 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2026 | 2887 | 0.120 |
Why?
|
| Neonatal Screening | 3 | 2024 | 204 | 0.120 |
Why?
|
| rab27 GTP-Binding Proteins | 1 | 2016 | 5 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2019 | 226 | 0.120 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 215 | 0.120 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 61 | 0.120 |
Why?
|
| Interferon Type I | 2 | 2021 | 119 | 0.120 |
Why?
|
| Diarrhea | 1 | 2017 | 314 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 77 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 148 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 373 | 0.110 |
Why?
|
| Pedigree | 3 | 2020 | 1672 | 0.110 |
Why?
|
| Phenotype | 4 | 2026 | 4464 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 1206 | 0.100 |
Why?
|
| Lung Diseases | 2 | 2019 | 397 | 0.100 |
Why?
|
| Fontan Procedure | 1 | 2016 | 180 | 0.100 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2022 | 14 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2022 | 55 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2023 | 191 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 613 | 0.090 |
Why?
|
| Texas | 1 | 2020 | 3648 | 0.090 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 821 | 0.090 |
Why?
|
| Genetic Therapy | 2 | 2023 | 711 | 0.090 |
Why?
|
| BCG Vaccine | 1 | 2022 | 109 | 0.090 |
Why?
|
| Age of Onset | 2 | 2025 | 594 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2026 | 668 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1026 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2023 | 293 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1826 | 0.080 |
Why?
|
| Middle Aged | 6 | 2025 | 28329 | 0.080 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 359 | 0.080 |
Why?
|
| Aged | 5 | 2025 | 20831 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 1542 | 0.080 |
Why?
|
| Survival Rate | 3 | 2020 | 2112 | 0.070 |
Why?
|
| Unrelated Donors | 2 | 2020 | 72 | 0.070 |
Why?
|
| Disease Management | 2 | 2025 | 555 | 0.070 |
Why?
|
| Contracture | 1 | 2019 | 26 | 0.070 |
Why?
|
| RNA | 1 | 2022 | 511 | 0.070 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 43 | 0.070 |
Why?
|
| Facies | 1 | 2019 | 157 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2019 | 154 | 0.070 |
Why?
|
| Intestinal Diseases | 1 | 2019 | 67 | 0.070 |
Why?
|
| Mice | 2 | 2022 | 18164 | 0.070 |
Why?
|
| Genomics | 1 | 2016 | 1617 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2019 | 82 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2023 | 1570 | 0.070 |
Why?
|
| Homeostasis | 1 | 2022 | 711 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 204 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2026 | 12841 | 0.070 |
Why?
|
| Growth Disorders | 1 | 2019 | 182 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2574 | 0.070 |
Why?
|
| Viremia | 1 | 2018 | 130 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2020 | 404 | 0.060 |
Why?
|
| Registries | 2 | 2025 | 1608 | 0.060 |
Why?
|
| Allografts | 2 | 2017 | 220 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 777 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 335 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 298 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 372 | 0.060 |
Why?
|
| Monitoring, Immunologic | 1 | 2026 | 15 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 4848 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 383 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2019 | 410 | 0.060 |
Why?
|
| Microcephaly | 1 | 2019 | 348 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 634 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 902 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 792 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2019 | 383 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 337 | 0.060 |
Why?
|
| Pituitary Gland | 1 | 1995 | 73 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2026 | 187 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2022 | 17552 | 0.050 |
Why?
|
| Cell Line | 2 | 2020 | 2554 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5161 | 0.050 |
Why?
|
| NADPH Oxidases | 1 | 2025 | 109 | 0.050 |
Why?
|
| Pituitary Neoplasms | 1 | 1995 | 74 | 0.050 |
Why?
|
| Europe | 1 | 2025 | 360 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 1881 | 0.050 |
Why?
|
| ROC Curve | 1 | 2026 | 609 | 0.050 |
Why?
|
| Adenoma | 1 | 1995 | 143 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2026 | 637 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2023 | 65 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 978 | 0.050 |
Why?
|
| Meningioma | 1 | 1995 | 148 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 964 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 89 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 250 | 0.040 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1088 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2016 | 472 | 0.040 |
Why?
|
| Glycolipids | 1 | 2021 | 33 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 3314 | 0.040 |
Why?
|
| Wiskott-Aldrich Syndrome Protein Family | 1 | 2020 | 8 | 0.040 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cytidine Deaminase | 1 | 2020 | 31 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2058 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 42 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 179 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2020 | 23 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2021 | 146 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 4032 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1392 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 118 | 0.040 |
Why?
|
| Transplantation Chimera | 1 | 2019 | 45 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 558 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 287 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2023 | 542 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 547 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 277 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1485 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 499 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 246 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 328 | 0.040 |
Why?
|
| Calcium | 1 | 2023 | 1008 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 208 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 66 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.030 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 33 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 331 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 309 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2018 | 112 | 0.030 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2017 | 3 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2017 | 26 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 127 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 361 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 237 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2018 | 201 | 0.030 |
Why?
|
| Pyrroles | 1 | 2018 | 188 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1215 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 228 | 0.030 |
Why?
|
| Piebaldism | 1 | 2016 | 3 | 0.030 |
Why?
|
| Albinism | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 412 | 0.030 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2016 | 19 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1872 | 0.030 |
Why?
|
| Consanguinity | 1 | 2016 | 115 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2824 | 0.030 |
Why?
|
| Exons | 1 | 2018 | 759 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2016 | 153 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 1995 | 1306 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1157 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2016 | 194 | 0.030 |
Why?
|
| Family | 1 | 2018 | 586 | 0.030 |
Why?
|
| Base Sequence | 1 | 2018 | 2729 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 345 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2016 | 287 | 0.020 |
Why?
|
| Brain | 1 | 1995 | 3146 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 525 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2553 | 0.020 |
Why?
|
| Risk Factors | 2 | 2017 | 10952 | 0.020 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2016 | 395 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1650 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 6403 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3813 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3025 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 2823 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 1177 | 0.020 |
Why?
|
| Prolactin | 1 | 1995 | 142 | 0.010 |
Why?
|
| Radiography | 1 | 1995 | 740 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 1336 | 0.010 |
Why?
|